Business Wire

ALPEGA

12.3.2024 15:58:32 CET | Business Wire | Press release

Share
Alpega Hits New Heights: Exceeds 'Rule of 40' Milestone with Stellar 2023 Results

Alpega, a leading global logistics SaaS software company, proudly announces its remarkable achievements for the fiscal year 2023, significantly surpassing targets for the third consecutive year. Alpega exceeded revenue and EBITDA objectives underpinned by strong bookings and new business opportunities, which is testimony to the strong traction that the Alpega solutions have with our customers. This success marks a significant milestone as Alpega now surpasses the prestigious 'Rule of 40' territory, a hallmark of excellence for SaaS software companies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305956634/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Alpega)

"In 2023, our remarkable performance underscores Alpega's steadfast commitment to delivering exceptional value to our customers." declared Todd DeLaughter, Alpega CEO. "Our core competency lies in leveraging our extensive carrier-based assets to provide tangible benefits to both shippers and carriers across a diverse range of solutions in Execution, Planning, Sourcing and Payments. As the sole SaaS provider offering Transport Management Systems (TMS) for shippers alongside an 80,000-strong open carrier network, covering approximately 10% of all commercial trucks in Europe, we lead the charge in innovation and efficiency. With these carriers connected through three premier freight exchanges in Europe, boasting strong leadership in Iberia, Romania, and Central and Southeastern European countries, we offer unparalleled connectivity and efficiency, facilitating the seamless matching of available freight loads with transportation capacity."

Alpega's ability to consistently exceed expectations and achieve such remarkable milestones is a testament to its unwavering dedication to excellence and customer satisfaction. As the company continues to push boundaries and redefine industry standards, it remains poised for even greater success in the years ahead.

Alpega

Alpega is a leading global logistics SaaS software company, dedicated to delivering end-to-end solutions that comprehensively address all transport requirements. Our mission is to empower shippers and carriers through efficient digitalization to meet today’s logistics challenges, driving smarter logistics for a greener tomorrow.

Drawing on extensive carrier-based assets, Alpega delivers tangible benefits across Execution, Planning, Sourcing and Payment solutions. As the sole SaaS provider offering Transport Management Systems (TMS) for shippers, coupled with an 80,000-strong open carrier network covering around 10% of all commercial trucks in Europe, we are at the forefront of innovation and efficiency. For our carriers, our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.

With over three decades of expertise in transportation, we empower businesses to streamline their supply chain planning and execution, resulting in reduced costs and heightened visibility. Alpega's suite of solutions synergistically generates added value for our customers. Our community comprises 80,000 carriers and 200,000 members, seamlessly connected electronically each day to efficiently manage vital transport operations. Operating in 80 countries globally, Alpega boasts a diverse team of over 600 professionals representing 31 nationalities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305956634/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye